IVERIC bio Inc (ISEE)

NASDAQ
Currency in USD
Disclaimer
39.950
0.000
(0.00%)
Closed
Trading near 52-week High
Day's Range
39.850
39.990
52 wk Range
9.390
39.990
Volume
0
Prev. Close
39.95
Open
39.86
Day's Range
39.85-39.99
52 wk Range
9.39-39.99
Volume
0
Average Vol. (3m)
5,050,687
1-Year Change
163.52%
Shares Outstanding
137,976,851
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Daily
Weekly
Monthly
More
How do you feel today about ISEE?
Vote to see community's results!
or

IVERIC bio Inc Company Profile

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed a Phase 2/3 clinical trial; GATHER2 is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in a Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high-temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 which has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprise the miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and the miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). IVERIC bio, Inc. was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Income Statement